Tiffany Zigras

Dr. Tiffany Zigras

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
AKAnjali Kulkarni
Anjali Kulkarni
NDNupur Dogra
Nupur Dogra
TZTiffany Zigras
Tiffany Zigras
Primary vaginal cancer is a rare gynecologic malignancy. Given the rarity of the disease, standardized approaches to management are limited, and a great variety of therapeutic conditions are endorsed. This paper reviews advances in surgical approaches, radiation, chemoradiation, and immunotherapy. Advances in surgical management including the increasing use of laparoscopic and endoscopic approaches, as well as the novel techniques in vaginal reconstruction, are reviewed. Concurrent chemoradiation remains a mainstay of treatment for vaginal cancer and has improved local control of disease and overall survival. Additionally, with metastatic disease or situations where toxicity from CCRT is unacceptable, systemic therapies including immunotherapy approaches are reviewed.

3 September 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
CLCaitlin Lazurko
Caitlin Lazurko
RLRevital Linder
Revital Linder
KPKate Pulman
Kate Pulman
GLGenevieve Lennox
Genevieve Lennox
TFTomer Feigenberg
Tomer Feigenberg
TZTiffany Zigras
Tiffany Zigras
Serous epithelial ovarian cancer, classified as either high-grade (90%) or low-grade (10%), varies in molecular, histological, and clinicopathological presentation. Low-grade serous ovarian cancer (LGSOC) is a rare histologic subtype that lacks disease-specific evidence-based treatment regimens. However, LGSOC is relatively chemo-resistant and has a poor response to traditional treatments. Alternative treatments, including biologic therapies such as bevacizumab, have shown some activity in LGSOC. Thus, the objective of this systematic review is to determine the effect and safety of bevacizumab in the treatment of LGSOC. Following PRISMA guidelines, Medline ALL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Embase all from the OvidSP platform, ClinicalTrials.gov, International Clinical Trials Registry Platform, International Standard Randomised Controlled Trial Number Registry were searched from inception to February 2022. Articles describing bevacizumab use in patients with LGSOC were included. Article screening, data extraction, and critical appraisal of included studies were completed by two independent reviewers. The effect of bevacizumab on the overall response rate, progression-free survival, overall survival, and adverse effects were summarized. The literature search identified 3064 articles, 6 of which were included in this study. A total of 153 patients were analyzed; the majority had stage IIIC cancer (56.2%). The overall median response rate reported in the studies was 47.5%. Overall, bevacizumab is a promising treatment for LGSOC, with response rates higher than traditional treatment modalities such as conventional chemotherapy, and is often overlooked as a treatment tool. A prospective clinical trial evaluating the use of bevacizumab in LGSOC is necessary to provide greater evidence and support these findings.

9 June 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
TZTiffany Zigras
Tiffany Zigras
MMMarie-Hélène Mayrand
Marie-Hélène Mayrand
CBCeline Bouchard
Celine Bouchard
SSShannon Salvador
Shannon Salvador
LELua Eiriksson
Lua Eiriksson
JBJames Bentley
James Bentley
The purpose of this paper is to provide evidence-based guidance on the management of a positive human papilloma virus (HPV) test and to provide guidance around screening and HPV testing for specific patient populations. The guideline was developed by a working group in collaboration with the Gynecologic Oncology Society of Canada (GOC), Society of Colposcopists of Canada (SCC), and the Canadian Partnership Against Cancer. The literature informing these guidelines was obtained through a systematic review of relevant literature by a multi-step search process led by an information specialist. The literature was reviewed up to July 2021 with manual searches of relevant national guidelines and more recent publications. The quality of the evidence and strength of recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. The intended users of this guideline include primary care providers, gynecologists, colposcopists, screening programs, and healthcare facilities. The implementation of the recommendations will ensure an optimum implementation of HPV testing with a focus on the management of positive results. Recommendations for appropriate care for underserved and marginalized groups are made.

1 October 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
CLCaitlin Lazurko
Caitlin Lazurko
MCMitchell Clark
Mitchell Clark
KPKate Pulman
Kate Pulman
GLGenevieve Lennox
Genevieve Lennox
TMTaymaa May
Taymaa May
TZTiffany Zigras
Tiffany Zigras

1 May 2021 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
GLGenevieve K. Lennox
Genevieve K. Lennox
MCMitchell Clark
Mitchell Clark
TZTiffany Zigras
Tiffany Zigras
MRMarjan Rouzbahman
Marjan Rouzbahman
GHGuangming Han
Guangming Han
LGLilian Gien
Lilian Gien

22 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CLCaitlin Lazurko
Caitlin Lazurko
TFTomer Feigenberg
Tomer Feigenberg
JMJoan Murphy
Joan Murphy
KPKate Pulman
Kate Pulman
GLGenevieve Lennox
Genevieve Lennox
TZTiffany Zigras
Tiffany Zigras
Borderline ovarian tumors (BOTs) are non-invasive tumors frequently diagnosed in young patients. Surgical removal of the uterus, fallopian tubes, ovaries, and omentum is considered definitive management, however fertility-sparing approach is a recognized option. Surveillance is important due to known recurrence, but there is controversy over the effectiveness of follow-up modalities. The objective is to determine the efficacy of ultrasound screening in identifying tumor recurrence. This retrospective chart review evaluated all patients consulted and/or treated surgically at our institution from January 2015 to June 2020 diagnosed with BOT. Patients were excluded if concurrently diagnosed with another gynecologic malignancy, did not have yearly ultrasound follow-up, or were lost to follow-up. This study included 56 patients, 17 of whom underwent fertility preserving surgery. The overall rate of recurrence was 10.7%; with recurrence rates of 23.5% for the fertility preserving surgery population and 5.1% for the definitive surgery population. Ultrasound first identified 5 of the 6 (83.3%) recurrences. Overall time to recurrence was 51.5 months. In conclusion, recurrences were identified on routine ultrasound screening prior to symptom onset or detection via physical exam in 83.3% of cases. While the best modality of follow-up remains controversial, this review provides evidence supporting the use of routine ultrasound follow-up for early detection of BOT recurrence.